Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase11Abbreviations: BVdU, (E)-5-(2-bromovinyl)-2′-deoxyuridine; BVdUMP, (E)-5-(2-bromovinyl)-2′-deoxyuridine 5′-monophosphate; NB1011, (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl l-methoxyalaninylphosphoramidate; COSY, correlated spectroscopy; DCI, direct current ionization; DMF, N,N-dimethylformamide; dUMP, 2′-deoxyuridine 5′-monophosphate; ECTA, enzyme-catalyzed therapeutic agent; 5-FU, 5-fluorouracil; 5-FdUMP, 5-fluoro-2′-deoxyuridine 5′-monophosphate; RFU, relative fluorescence units; THF, N5,N10-methylene tetrahydrofolate; TBDMS, tert-butyldimethylsilyl; and TS, thymidylate synthase (EC 2.1.1.45).-Reference-Cited by-同舟云学术

Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase11Abbreviations: BVdU, (E)-5-(2-bromovinyl)-2′-deoxyuridine; BVdUMP, (E)-5-(2-bromovinyl)-2′-deoxyuridine 5′-monophosphate; NB1011, (E)-5-(2-bromovinyl)-2′-deoxy-5′-uridyl phenyl l-methoxyalaninylphosphoramidate; COSY, correlated spectroscopy; DCI, direct current ionization; DMF, N,N-dimethylformamide; dUMP, 2′-deoxyuridine 5′-monophosphate; ECTA, enzyme-catalyzed therapeutic agent; 5-FU, 5-fluorouracil; 5-FdUMP, 5-fluoro-2′-deoxyuridine 5′-monophosphate; RFU, relative fluorescence units; THF, N5,N10-methylene tetrahydrofolate; TBDMS, tert-butyldimethylsilyl; and TS, thymidylate synthase (EC 2.1.1.45).

Published:2001-01 Issue:2 Volume:61 Page:179-189
ISSN:0006-2952
Container-title:Biochemical Pharmacology
language:en
Short-container-title:Biochemical Pharmacology

Author:

Lackey David B.,Groziak Michael P.,Sergeeva Maria,Beryt Malgorzata,Boyer Christopher,Stroud Robert M.,Sayre Peter,Park John W.,Johnston Patrick,Slamon Dennis,Shepard H.Michael,Pegram Mark

Publisher

Elsevier BV

Subject

Pharmacology,Biochemistry

Reference24 articles.

1. Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein;Lee;Exp Cell Res,1997

2. Genetic instability as a consequence of inappropriate entry into and progression through S-phase;Almasan;Cancer Metastasis Rev,1995

3. S100A4 involvement in metastasis;Bjornland;Cancer Res,1999

4. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines;Li;Proc Natl Acad Sci USA,1995

5. Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy;Lonn;Cancer,1996

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. smProdrugs: A repository of small molecule prodrugs;European Journal of Medicinal Chemistry;2023-03

2. DESIGN, SYNTHESIS, AND APPLICATIONS OF NUCLEOSIDE PHOSPHATE AND PHOSPHONATE PRODRUGS;Nucleic Acids in Medicinal Chemistry and Chemical Biology;2022-12-16

3. An overview of ProTide technology and its implications to drug discovery;Expert Opinion on Drug Discovery;2021-05-24

4. ProTides of BVdU as potential anticancer agents upon efficient intracellular delivery of their activated metabolites;Bioorganic & Medicinal Chemistry Letters;2016-12

5. Nucleoside Phosphate and Phosphonate Prodrug Clinical Candidates;Journal of Medicinal Chemistry;2016-09-08